{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T17:32:40Z","timestamp":1757611960115,"version":"3.44.0"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T00:00:00Z","timestamp":1750118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T00:00:00Z","timestamp":1750118400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s10620-025-09166-w","type":"journal-article","created":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T13:33:00Z","timestamp":1750167180000},"page":"2944-2946","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Annual Infliximab Monitoring After Treatment Optimization"],"prefix":"10.1007","volume":"70","author":[{"given":"Natsuki","family":"Ishida","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Sugimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,17]]},"reference":[{"key":"9166_CR1","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","volume":"359","author":"SB Hanauer","year":"2002","unstructured":"Hanauer SB, Feagan BG, Lichtenstein GR et al. Maintenance infliximab for Crohn\u2019s disease: the ACCENT I randomised trial. Lancet 2002;359:1541\u20131549.","journal-title":"Lancet"},{"key":"9166_CR2","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1056\/NEJMoa050516","volume":"353","author":"P Rutgeerts","year":"2005","unstructured":"Rutgeerts P, Sandborn WJ, Feagan BG et al. Infliximab for induction and maintenance therapy for ulcerative colitis: ACT 1 and ACT 2 trials. N Engl J Med 2005;353:2462\u20132476.","journal-title":"N Engl J Med"},{"key":"9166_CR3","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1053\/j.gastro.2015.02.031","volume":"148","author":"N Vande Casteele","year":"2015","unstructured":"Vande Casteele N, Ferrante M, Van Assche G et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology 2015;148:1320-1329.e3.","journal-title":"Gastroenterology"},{"key":"9166_CR4","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-025-09032-9","author":"Y Lim","year":"2025","unstructured":"Lim Y, Park B, Jeon K et al. Annual therapeutic drug monitoring in patients with inflammatory bowel disease during infliximab maintenance therapy: balancing efficacy with risk of pharmacokinetic failure. Dig Dis Sci. 2025. https:\/\/doi.org\/10.1007\/s10620-025-09032-9 (Published online April 29, 2025).","journal-title":"Dig Dis Sci"},{"key":"9166_CR5","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1053\/j.gastro.2018.01.004","volume":"154","author":"G D\u2019Haens","year":"2018","unstructured":"D\u2019Haens G, Vermeire S, Lambrecht G et al. Increasing infliximab dose based on symptoms, biomarkers, and serum drug concentrations does not increase clinical, endoscopic, and corticosteroid-free remission in patients with active luminal Crohn\u2019s disease. Gastroenterology 2018;154:1343-1351.e1.","journal-title":"Gastroenterology"},{"key":"9166_CR6","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1111\/j.1365-2036.2011.04612.x","volume":"33","author":"S Ben-Horin","year":"2011","unstructured":"Ben-Horin S, Chowers Y. Review article: loss of response to anti-TNF treatments in Crohn\u2019s disease. Aliment Pharmacol Ther 2011;33:987\u2013995.","journal-title":"Aliment Pharmacol Ther"},{"key":"9166_CR7","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1053\/j.gastro.2019.09.041","volume":"158","author":"A Sazonovs","year":"2020","unstructured":"Sazonovs A, Kennedy NA, Moutsianas L et al. HLA-DQA1*05 carriage associated with development of anti-drug antibodies to infliximab and adalimumab in patients with Crohn\u2019s disease. Gastroenterology 2020;158:189\u2013199.","journal-title":"Gastroenterology"},{"key":"9166_CR8","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1159\/000515361","volume":"6","author":"A Yoshida","year":"2021","unstructured":"Yoshida A, Matsuoka K, Ueno F, Morizane T, Endo Y, Hibi T. Serum PR3-ANCA is a predictor of primary nonresponse to anti-TNF-\u03b1 agents in patients with ulcerative colitis. Inflamm Intest Dis 2021;6:117\u2013122.","journal-title":"Inflamm Intest Dis"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-025-09166-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-025-09166-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-025-09166-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T05:17:26Z","timestamp":1756963046000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-025-09166-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,17]]},"references-count":8,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["9166"],"URL":"https:\/\/doi.org\/10.1007\/s10620-025-09166-w","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"type":"print","value":"0163-2116"},{"type":"electronic","value":"1573-2568"}],"subject":[],"published":{"date-parts":[[2025,6,17]]},"assertion":[{"value":"17 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}